Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance

Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance

(2021) David P. Nicolau et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

(2021) Abigail M. Rubio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

(2020) Ivan Titov et al.   CLINICAL INFECTIOUS DISEASES

Carbapenem Non-susceptible Pseudomonas aeruginosa from Intensive Care Units in the United States: A Potential Role for New β-lactam Combination Agents

(2019) Tomefa E Asempa et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

(2019) Katherine Young et al.   BMC MICROBIOLOGY

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam

(2019) Pratik Bhagunde et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Monte Carlo Simulation Methodologies for β‐Lactam/β‐Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments

(2019) James M. Kidd et al.   JOURNAL OF CLINICAL PHARMACOLOGY

in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli

(2018) Suzannah M. Schmidt-Malan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model

(2018) Jin Wu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

(2018) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

633

(2018) Kevin Akers et al.   CRITICAL CARE MEDICINE

Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory

(2016) Mordechai Grupper et al.   CLINICAL MICROBIOLOGY REVIEWS

Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients

(2015) Michael Schleibinger et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study

(2015) Angela Huttner et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model

(2014) Eleftheria Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients

(2014) Jan J. De Waele et al.   INTENSIVE CARE MEDICINE

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Augmented Renal Clearance in the ICU

(2013) Andrew A. Udy et al.   CRITICAL CARE MEDICINE

Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring

(2012) Uwe Tröger et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS